Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
CRANBURY, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell , President and Chief Operating Officer, and Jeff Castelli , Chief Portfolio Officer and Head of Gene
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
            2Q19 Galafold ® (migalastat) Revenue of $44.1M Represents Highest Quarterly  Growth Since Launch Driven by Continued Strong Global Uptake  Reiterating FY19 Revenue Guidance of $160M-$180M Full Enrollment in Pompe Pivotal Study of AT-GAA on Track by YE19 Significant Progress Across
View HTML
Toggle Summary Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina
          First Oral Precision Medicine Approved for People Living with Fabry Disease with an Amenable Mutation in Argentina First Amicus Regulatory Approval in Latin America CRANBURY, N.J. , and BUENOS AIRES, Argentina , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today
View HTML
Toggle Summary Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
 Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment Conference Call at 8:30 a.m. ET Today CRANBURY, N.J. , Aug.
View HTML
Toggle Summary Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
CRANBURY, N.J. , July 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2019 .
View HTML
Toggle Summary Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J. , July 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc.
View HTML
Toggle Summary Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration
         Supports Clinical and Commercial Supply Needs for Multiple Batten Disease Programs Advances Amicus Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J. , July 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic
View HTML
Toggle Summary Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership
Jill Weimer , PhD named Senior Vice President of Discovery Research and Gene Therapy Science Simon Jordan named Senior Vice President of International CRANBURY, N.J. , June 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced two new additions to the Senior Leadership
View HTML
Toggle Summary Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J. , June 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 18,720,930 shares of its common stock, including 2,441,860 shares of common stock sold pursuant to
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences
CRANBURY, N.J. , June 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June. Upcoming Scientific Conference : Michael C. Diem , MD, Senior Vice President of Business and Corporate
View HTML